Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.

MLA

Saremi, Aramesh, et al. “Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, Feb. 2013, pp. 393–99. EBSCOhost, https://doi.org/10.1161/ATVBAHA.112.300346.

APA

Saremi, A., Schwenke, D. C., Buchanan, T. A., Hodis, H. N., Mack, W. J., Banerji, M., Bray, G. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Tripathy, D., DeFronzo, R. A., & Reaven, P. D. (2013). Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(2), 393–399. https://doi.org/10.1161/ATVBAHA.112.300346

Chicago

Saremi, Aramesh, Dawn C Schwenke, Thomas A Buchanan, Howard N Hodis, Wendy J Mack, Maryann Banerji, George A Bray, et al. 2013. “Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors.” Arteriosclerosis, Thrombosis, and Vascular Biology 33 (2): 393–99. doi:10.1161/ATVBAHA.112.300346.